SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 2, 2010

NEOSTEM, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware	0-10909	22-2343568
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

420 Lexington Avenue, Suite 450, New York, New York 10170
(Address of Principal Executive Offices)(Zip Code)

(212) 584-4180
Registrant's Telephone Number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

NeoStem, Inc. (the "Company") intends to use a slide presentation at its 2010 Annual Meeting of Stockholders to be held on June 2, 2010. The slide presentation is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01 is being furnished pursuant to Item 7.01 of Form 8-K and, in accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including, without limitation, the slide presentation attached hereto as Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, *provided, however,* that slides 1 through 28 of the slide presentation are intended to be deemed "filed" rather than "furnished" under the Exchange Act.

Forward Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. Forward-looking statements represent our management's judgment regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. All statements other than statements of historical fact included in this Current Report on Form 8-K are forward-looking statements. The Company cannot guarantee the accuracy of the forward-looking statements, and you should be aware that the Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the statements under "Risk Factors" contained in the Company's reports filed with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Slide Presentation, dated June 2010 (Exhibit 99.1 is furnished as part of this Current Report on Form 8-K pursuant to Item 7.01 of Form 8-K and, in accordance with General Instruction B.2 of Form 8-K, Exhibit 99.1 shall not be deemed to be "filed," *provided, however,* that slides 1 through 28 of Exhibit 99.1 are intended to be deemed "filed" rather than "furnished" under the Exchange Act).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOSTEM, INC.

By: /s/ Catherine M. Vaczy
Name: Catherine M. Vaczy
Title: Vice President and General Counsel

Date: June 2, 2010

NEOSTEM, INC. ("NBS")

Investor Presentation

June 2010

NeoStem

YOUR CELLS • YOUR USE • YOUR LIFE

WWW.NEOSTEM.COM

Forward-Looking Statements

Included in this presentation are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this prospectus, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "plan," "intend," "may," "will," "expect," "believe," "could," "anticipate," "estimate," or "continue" or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements. Additionally, statements concerning our ability to successfully develop the adult stem cell business at home and abroad, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the role of VSEL™ Technology in that future, and the potential revenue growth of such business are forward-looking statements. Our future operating results are dependent upon many factors, and our further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. Forward-looking statements may not be realized due to a variety of factors, including, without limitation, (i) our ability to manage the business despite continuing operating losses and cash outflows; (ii) our ability to obtain sufficient capital or a strategic business arrangement to fund its operations and expansion plans, including meeting its financial obligations under various licensing and other strategic arrangements and the successful commercialization of the relevant technology; (iii) our ability to build the management and human resources and infrastructure necessary to support the growth of the business; (iv) competitive factors and developments beyond our control; (v) scientific and medical developments beyond our control; (vi) our inability to obtain appropriate governmental licenses or any other adverse effect or limitations caused by government regulation of the business; (vii) whether any of our current or future patent applications result in issued patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business; (viii) whether any potential strategic benefits of various licensing transactions will be realized and whether any potential benefits from the acquisition of these new licensed technologies will be realized; (ix) whether we can obtain the consents we may require to sublicensing arrangements from technology licensors in connection with technology development; (x) factors regarding our business in China and, generally, regarding doing business in China, including through our variable interest entity structure and other factors disclosed in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2010 and Quarterly Report on Form 10-Q filed on May 17, 2010; and (xi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings".

All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after the date initially filed or published, to reflect the occurrence of unanticipated events or otherwise, except to the extent required by federal securities laws.

2009 – YTD 2010 Accomplishments

- **Unprecedented collaboration with Vatican's Pontifical Council for Culture**
  - Advance adult stem cell understanding, research and therapeutic applications
- **Significantly strengthened adult stem cell therapeutic platform**
  - Exclusive worldwide license for stem cell technologies and applications
    - Anti-aging, cosmetic, wound healing, musculoskeletal disease
  - VSEL™ technology data reported at ASH
  - NIH Grant & University of Michigan sponsored research agreement
    - Stem cells for bone defects
- **Continued expansion of U.S. adult stem cell collection network**
  - Added new collection centers – NJ, TX, MA

2009 – YTD 2010 Accomplishments (Cont)

- **Evolved into an international biopharma company with operations in China**
  - Built platform and infrastructure in China to establish partnerships to commercialize stem cell applications and generate near-term revenues
  - Signed strategic partnerships with leading hospitals and research organizations to advance development and commercialization of stem cell applications
    - Partnered with Wendeng Orthopedic Hospital, Enhance Biomedical to create near-term commercial potential
  - Acquired 51% stake in Suzhou Erye, profitable and growing pharma company
    - Revenue diversity opportunities in the near- and long-term
    - Accelerate pace to profitability
- **Broadened and strengthened board of directors and scientific advisory board**
- **Raised >$25 million**

Company Overview

Summary Profile	
Ticker	NBS (AMEX)
2010 Trading Range	$1.26 - $3.50
Market Cap [1]	$146 million
Corporate Headquarters	NYC
Pharmaceutical Subsidiary	Suzhou Erye (China)

[1] *Based on 54 million shares outstanding and $2.72 closing price on 6/1/10.*

Pharmaceuticals – China

Suzhou Erye – Profitable & Growing

- Vertically-integrated manufacturer of generic antibiotic Rx products and APIs
  - 8 cGMP-certified production lines
- Extensive distribution network throughout PRC
  - No significant customer concentration
- 60% of current drug portfolio covered by insurance (expected to grow)
- Revenue nearly doubled from 2007 to 2009; robust growth continue in 1Q 2010



Diversified Product Portfolio

No single drug accounting for >10% of sales

Top Ten Drugs in 2009 (52.6% of Total Sales)	
Drugs	**% of Sales**
Acetylspiramycin	7.5%
Oxacillin Sodium	7.2%
Mezlocillin Sodium for injection	6.9%
Amoxicillin Sodium & Sulbactam Sodium for injection	6.5%
Cefoperazone Sodium & Sulbactam Sodium for injection	5.2%
Amoxicillin & Potassium Clavulanate for injection	4.6%
Furbencillin Sodium for injection	4.0%
Ceftizozime Sodium for injection	3.9%
Ampivillin Sodium & Sulbactam Sodium for injection	3.7%
Azlocillin Sodium for injection	3.1%

Large Chinese Pharmaceutical Opportunity

- **China announced $124 billion budget to improve healthcare system in 2009-11**
  - Provide universal medical service to China's 1.3 billion population
  - New Rural & Urban Cooperative Medical Insurance System – at least 90% of population will be covered by 2011
  - Construction of 30,000 new hospitals, clinics and healthcare centers
- **Pharmaceutical market forecasted to reach $78 billion by 2013**
  - China to become third largest drug market (behind U.S. and Japan)
- **Antibiotics market $8+ billion in 2007**
  - 24% annual average growth rate for previous three years
  - Many antibiotics will be covered as "essential medicines" under the new healthcare insurance system giving end users 100% payment coverage

Significant Manufacturing Capacity Expansion

- New facility completed in 2009
  - Penicillin sterile API facility for solvent crystallization and freeze dried raw material drugs with two cGMP lines approved
- 2010 / 2011 targets
  - Penicillin powder for injection facility
  - Cephalosporin powder for injection facility
  - Oral API facility
  - Freeze dried powder for injection facility
  - Capsule facility
  - Sterile cephalosporin API facility
- Future
  - Additional buildings available for expansion

Platform to Drive Sustainable Growth

- Current pipeline of 7 Rx drugs
  - Two pending launch, two pending approval, three in active development
- External growth strategy
  - Enhance R & D activities in China and the U.S.
  - In-license drugs with proven efficacy & efficacy that leverages new facility
  - Expand indications beyond anti-infectives

Pipeline Drugs	Form/Dosage	Indication	Status
Omeprazole	Capsules (20mg)	GERD	Approved – Pending Launch
Cloxacillin sodium	Sterile API	Anti-infective	Approved – Pending Launch
Clindamycin phosphate	Injection (0.3, 0.6G)	Antibiotic	Pending SFDA Review
Adefovir	API & Capsules (10mg)	Hepatitis B / HIV	Pending SFDA Review
Faropenem sodium	API	Anti-infective	In Clinical Trials
Faropenem sodium	Tablet (0.1G)	Anti-infective	In Clinical Trials
Tiopronin Enteric-Coated	Capsules (0.1G)	Hepatitis B	In Clinical Trials

Adult Stem Cell Initiatives
U.S. & China

Stem Cell Background



Two main types of stem cells

- Adult Stem Cells - isolated from adult tissues
  - Act as tissue repair and maintenance system
  - Multipotent
  - Reduces risk of immune rejection
  - Successful use in human therapies (i.e. bone marrow transplant) for 40 years
- Embryonic Stem Cells – isolated from blastocysts (early stage embryo)
  - Develop into specialized embryonic tissues
  - Pluripotent
  - Controversial due to ethical and moral dilemmas
  - No history in human therapeutic use

Stem Cell Market Opportunity

Attractive market with both near- and longer-term opportunities

- **Fragmented market with significant barriers to entry**
- **Commercial opportunities already being realized ex-U.S.**
  - Expedited clinical and regulatory pathways compared to U.S.
  - Regulated by the Ministry of Health in China
- **Foundation for future market growth in the U.S.**
  - 40+ years treatment for cancer and anemia through bone marrow transplants
  - 2,800+ stem cell clinical trials ongoing *(www.clinicaltrials.gov)*
  - 16+ stem cell products expected to be approved by FDA, resulting in 1.9 million annual procedures, by 2017 *(RRY Publications)*
- **Global stem cell product market expected to reach $88 billion by 2014**
  (Markets and Markets)

NeoStem and Vatican's Pontifical Council

Planned Joint Initiatives

- **Launch International Conference at the Vatican in 2011**
  - Adult Stem Cell research, including VSEL™ Technology, with thought leaders from all over the world
- **Derive potential financial resources from multiple sources to support VSEL™ Technology research**
  - Pontifical Council undertaken to commit $1 million to the joint initiatives
  - Include two charitable foundations: Stem for Life and STOQ
- **Prepare academic courses with interdisciplinary approach for faculties of bioethics, theology and philosophy**
  - Worldwide distribution – Catholic Universities, other institutions of secondary education
- **Develop and launch Interdisciplinary Open Journal on Adult Stem Cells**
  - First edition focus: VSEL™ Technology, its broad applicability, ethical and theological interpretation
- **Build website for International Conference**
  - Long-term vision: THE Adult Stem Cell resource for theological, philosophical and ethical issues in stem cells

Leading U.S. Stem Cell Operations

A. Pioneer in adult stem cell banking

- **Recurring revenue stream**
- **Minimally invasive procedure ("apheresis")**
- **Growing network in major metropolitan areas**
  - Expand to ten centers by end of 2010
- **East and West Coast processing locations through PCT**

B. Adult stem cell research

- **Global Research HQ – Cambridge, MA**
  - Advanced equipment & talented research team
- **VSEL™ Technology (very small embryonic-like stem cells)**
  - Potentially vast therapeutic applications

Expansive Adult Stem Cell Therapies

Collection Process

- Low-dose, short course, GCSF induction of stem cell mobilization
- Collection of adult stem cells from peripheral blood of healthy individuals for future use
- Process for preparation and storage of collected stem cells
- Multiple storage vials containing different stem cell types

Cell Type

- Identification, isolation, and use of very small embryonic-like stem cells (VSEL™)
- Treatment of diseases with VSEL™

Cosmetic Surgery

Delivery Technology

- Accelerated skin wound healing with stem cells and fibrin

Before | After



- Age-related tissue loss in face or other selected areas with stem cells and growth factor s
- Percutaneous administration of stem cells for cartilage and disc repair and fractures

Non-closing fracture | 2 months post-BMSC



Patent & Patent Application Portfolio

	Patent/Application Titles	Country	Patent/Application Numbers	Date Filed
Collection Process	"Elective Collection and Banking of Autologous Peripheral Blood Stem Cells."	US	11/396,238	03/30/06
		Canadian	2548580	04/05/04
	"Processing Procedure for Peripheral Blood Stem Cells."	US	11/763,655	06/15/07
		European	07809600.95	06/15/07
		Chinese	200780030328.6	06/15/07
	"Mesenchymal Stem Cells Isolated from Mobilized Peripheral Blood"	US	61/266,825	12/04/09
	"Method of Isolation of Stem Cell Populations from Peripheral Blood Using Size-Based Separation"	US	61/266,860	12/04/09
VSEL™ Technology	"Very Small Embryonic-Like Stem Cells and Methods of Isolating and Using the Same."	US	12/096,754	11/02/06
		US	12/261,958	10/30/08
		European	06827358.0	11/02/06
		Chinese	200680052508.X	11/02/06
	"Transplantation of Very Small Embryonic-Like Stem Cells for Cardiac Repair Following Myocardial Infarction."	US	PCT/US2008/081832	10/30/08
	"Methods for Isolating Very Small Embryonic-Like Stem Cells from Cord Blood."	US	PCT/US2009/005414	09/30/09
Wound Healing	"Autologous Bone Marrow-Derived Cultured Mesenchymal Stem Cells Delivered in a Fibrin Spray Accelerate Healing in Murine and Human Cutaneous Wounds"	US	61/039,941	03/27/07
		US	12/413,250	03/27/09
		US	PCT/US2009/038666	03/27/09
Tissue Restoration	"Method and Compositions for Restoration of Age Related Tissue Loss in the Face or Selected Areas of the Body."	*US*	*Patent no 7414021 issued on 8/19/08*	
		US	12/218,334	07/14/08
	"Method and Composition for Restoration of Age Related Tissue Loss in the Face or Selected Areas of the Body."	US	61/175,275	05/04/09
Bone and Cartilage Repair	"Mesenchymal Stem Cell Isolation and Transplantation Method and System to be Used in a Clinical Setting."	US	60/761,441	01/24/06
		US	PCT/US2007/60889	01/23/07
		European	07762515.0	01/23/07
		Hong Kong	09103392.9	01/23/07
		Canadian	2640185	01/23/07
		US	12/161,911	11/07/08
	"Methods and Compositions for Optimized Expansion and Implantation of Mesenchymal Stem Cells."	US	11/773,774	07/05/07
		US	PCT/US2008/68202	06/25/08
	"Compositions to Promote Implantation and Engraftment of Stem Cells."	US	61/014,987	12/19/07
		US	PCT/US2008/87452	12/18/08
	"Compositions and Methods for Cartilage Repair."	US	61/036,551	03/14/08
		US	PCT/US2009/037126	03/13/09
	"Methods and Compositions for Intervertabral Disc Repair."	US	61/120,098	12/05/08
		US	61/154,874	02/24/09

Progressive Stem Cell Environment in China

- **Leverage platform to begin launching stem cell therapies in China in 2010**
  - Different clinical/regulatory pathway vs. U.S.
    - Ministry of Health instead of SFDA
  - More receptive of advanced therapeutics such as stem cell therapy
  - Broader consumer acceptance of non-traditional therapies
  - Favorable medical tourism trend
  - Government – healthcare reform, innovative technologies/therapies
- **Transfer knowledge and data to accelerate U.S. stem cell therapy development cost effectively**

China Stem Cells – 2010 Operational Targets

- **Launch first stem cell therapeutic procedure in orthopedics in PRC**
  - Wendeng launched in 1Q – revenue generation to start in summer 2010
- **Open first anti-aging & cosmetic treatment center in Taiwan**
  - Enhance launching adult stem cell collection and storage in 2Q 2010
  - Enhance to launch therapeutic applications in summer 2010
- **Initiate construction of Beijing stem cell facility**
  - Phase 1 started in April – estimated completion at year-end
- **Complete collaborative partnership for stem cell banking business**
- **Build additional collaborative relationships for future launches**
  - LOIs executed between Shandong Life Science and Technology Research Institute (NeoStem's China consultant) and Peking University Diabetes Center, Beijing Institute of Geriatrics, Ministry of Health and Shandong University

Stem Cell Platform Summary

- **Pioneer in autologous adult stem cell collection and storage**
  - Collection network continues to expand in the U.S. and building infrastructure in China to enhance opportunity
- **Diverse mix of exclusive advanced adult stem cell technologies and applications**
  - VSEL™ Technology, anti-aging/cosmetic, Primcel (wound healing), Regenexx™ (orthopedic)
- **Expansive and growing portfolio of patent and patent applications for stem cell type, process and applications**
- **State-of-the-art adult stem cell R&D lab staffed with talented team**
  - Explore proof of concept opportunities
- **Advancing stem cell therapeutic opportunities by through strategic partnerships in China's progressive environment**
  - Data transfer to accelerate U.S. stem cell therapy development

Financials

Key Financial Metrics (1)

	NeoStem, Inc. Three Months Ended March 31, 2010	NeoStem/CBH Proforma (2) Three Months Ended March 31, 2009
($ in 000's)		
Revenue		
Pharmaceuticals	15,775	12,691
Stem cell and others	58	45
Total revenues	15,833	12,736
Gross profit	4,982	4,069
R&D expenses	1,300	227
Net cash used in operations	(2,582)	NC*

	March 31, 2010	December 31, 2009
Cash & equivalents	11,418	7,159
Restricted cash	4,712	4,715
Total assets	122,003	108,894
Current liabilities	31,168	25,494
Total liabilities (3)	56,742	50,889
Total equity	65,261	58,005

(1) This table should be read in conjunction with the Company's full financial statements for these periods which may be found at www.sec.gov under "Search for Company Filings."
(2) NeoStem acquired China Biopharmaceutical Holding (CBH), including the 51% stake in Suzhou Erye, in October 2009.
(3) Includes $13.7 million attributable to the Company's Series C Convertible Redeemable Preferred Stock which is accounted for as a liability. On 5/17/10, the Series C was fully converted.
** NC – Not calculated*

Ownership & Equity Data (as of 6/1/10)

Ownership	% Outstanding	% Based on SEC Beneficial Ownership
Management & Directors (Excluding RimAsia)	4.5%	10.1%
EET / Fullbright (Erye Managers and Minority Interest Holder)	6.8%	7.9%
RimAsia	41.8%	45.9%
Enhance Biomedical Holdings (Strategic Partner)	7.5%	13.9%
Public / Other	39.4%	48.7%

Capitalization (Common Share Equivalent in 000s)	Shares Outstanding	% Outstanding
Convertible Redeemable Series B & C Preferred stock	10	NM
Common Stock	53,573	66.1%
Total Warrants; Average Exercise Price $2.73	17,278	21.3%
Total Options; Average Exercise Price $1.90	10,245	12.6%
Fully-diluted Shares Outstanding	81,106	100.0%

Source: Company filings

Management and Boards

Key Executives

Robin Smith, MD MBA CEO & Chairman of the Board	▪ MD – Yale; MBA – Wharton ▪ Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) ▪ Trustee of NYU Medical Center; Chairman of the Board of NYU Hospital for Joint Diseases (through November 2009) and Stem for Life Foundation
Jian Zhang General Manager, Suzhou Erye	▪ Joined Erye in 2003; extensive experience in the Chinese pharmaceutical industry ▪ Degree in Finance and Accounting from Central Television University ▪ Certified Public Accountant in China
Peter Sun, MD General Manager, NeoStem (China)	▪ Masters in Biotechnology & Pharmacology – University of British Columbia ▪ Licensed, endocrinologist; ~20 years of experience in pharmaceutical, biotech & medical ▪ Formerly with Sun Biomedical Labs; Panagin Pharma
Larry May Chief Financial Officer	▪ BS Business Administration – University of Missouri ▪ Formerly Treasurer & Controller at Amgen; SVP Finance & CFO at BioSource Intl ▪ Extensive experience building accounting, finance and IT operations
Chris Duignan, CPA Chief Accounting Officer & VP of Finance	▪ BS Accounting – Fairfield University ▪ Formerly Chief Financial Officer & Chief Accounting Officer at Enliven Marketing Technologies Corp. ▪ Formerly with PricewaterhouseCoopers, LLP
Catherine Vaczy, Esq VP and General Counsel	▪ BA – Boston College; JD – St. John's University ▪ Formerly VP of Legal and Associate General Counsel for Imclone Systems Inc. ▪ Formerly Corporate Counsel at Ross & Hardies, New York Office, Life Science Practice ▪ Member of the Board of Stem for Life Foundation
Alan Harris, MD PhD FACP FRCP VP of Drug Development and Regulatory Affairs	▪ MD – University of Strasbourg (France); PhD – Erasmus University (Netherlands) ▪ Currently Adjunct Prof of Pharmacology NYU Medical School; Formerly Assoc Prof of Medicine UCLA School of Medicine, Dir of Clinical Pharmacology Cedars-Sinai Medical Center ▪ Formerly with NPS Pharmaceuticals; Pfizer; Schering-Plough; Novartis
Anthony Salerno VP of Strategic Development and Academic Affairs	▪ BA College of the Holy Cross, Graduate School of Arts and Sciences (biochemistry & molecular biology), Harvard ▪ Over 25 years of entrepreneurial experience ▪ Previously VP Strategic Business Development GenomeQuest, Inc. (DNA sequencing bioinformatics); Director Marketing & Business Intelligence Agilent Technologies, Inc.; Founder & President VectorObjects LLC; MD BioDynamics; Snr Marketing Consultant Vysis Inc. (now part of Abbott)

Board of Directors

Robin Smith, MD, MBA **CEO and Chairman**	▪ See Key Executives
Eric Wei **Managing Partner, RimAsia Capital Partners**	▪ BS Mathematics & Economics – Amherst College; MBA – Wharton ▪ Experience – Founder/Managing Partner of RimAsia Capital Partners (private equity); Peregrine Capital, Prudential Securities, Lazard Freres, Citibank; Gilbert Global Equity PartnersCrimson Asia Capital Partners
Mingsheng Shi, Chairman of the Board of Suzhou Erye Pharmaceutical	▪ BSc Economics & Management – Party School of the Communist Party of China ▪ Professional title of Senior Economist ▪ Extensive experience in pharmaceutical industry in China
Steven Myers (Independent)	▪ BS Mathematics – Stanford University ▪ Experience – Founder/Chairman/CEO SM&A (competition management services); career in aerospace and defense sectors supporting DoD & NASA programs
Drew Bernstein, CPA (Independent)	▪ BS – University of Maryland Business School ▪ Licensed in State of New York; member AICPA, NYSSCPA and NSA ▪ Experience – Bernstein & Pinchuk LLP (member of BDO Seidman Alliance); PRC auditing; 200+ real estate transactions with $3B+ aggregate value; accountant and business advisor
Richard Berman (Independent)	▪ Over 35 years of venture capital, management, M&A experience ▪ Experience – Current Board of Directors of NexMed, Easylink Services International, Inc., Advaxis, Inc., Broadcaster, Inc., National Investment Managers
Edward Geehr, MD (Independent)	▪ BS – Yale University; MD – Duke University ▪ Experience – Abraxis Bio-Science; Allez Spine; IPC-The Hospitalist Company

Advisory Board Members

Wayne Marasco, MD, PhD (Chairman)	▪ Associate Professor, Dept of Cancer and Immunology & AIDS at Dana-Farber Cancer Institute; Associate Professor of Medicine at Harvard Medical School ▪ Leading NeoStem's independent research efforts and collaborations
Douglas Losordo, MD (ACC, ADA, ASGCT)	▪ Director of the Feinberg Cardiovascular Research Institute at Northwestern's Feinberg School of Medicine ▪ Associate Editor of *Circulation Research* and serves on the editorial boards of *Circulation*, *Vascular Medicine*, and *Stem Cells*, among others.
Vincent Falanga, MD	▪ Professor of Dermatology and Biochemistry at Boston University ▪ Chairman of Dermatology at Roger Williams Medical Center (RI)
Ron Rothenberg, MD (FACEP)	▪ MD – Columbia University ▪ Founder of California Health Span Institute; Attending Physician at Scripps Memorial Hospital; previously Clinical Professor at UCSD School of Medicine ▪ 10th M.D. in the world to be fully board certified by American Board of Anti-Aging Medicine
Mariusz Ratajczak, MD, PhD	▪ World renowned investigator in adult stem cell and co-inventor of NeoStem's exclusively licensed VSEL™ technology ▪ Director of Stem Cell Institute at James Graham Brown Cancer Center; Professor in Department of Microbiology and Immunology – University of Louisville
Richard Gatti, MD	▪ Professor at UCLA; Pathologist at UCLA Medical Center ▪ Early pioneer of bone marrow transplantation; leading authority in gene therapeutics ▪ Co-authored hundreds of papers on molecular ID/treatment of genetic disorders
Vincent Giampapa, MD	▪ Board Certified Plastic Reconstructive Surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at University of Medicine and Dentistry of NJ ▪ Director of Plastic Surgery Center Intl; The Giampapa Institute for Anti-Aging Medical Therapy
George Smith, MD	▪ Formerly NeoStem's Medical Director of Laboratory Operations ▪ Formerly with UCLA Pathology lab - established unique bone marrow service at Medical Center; Director of the UCLA Clinical Laboratories; Director of the Blood Bank, Chief of Clinical Pathology ▪ Part of research group that developed and defined HLA antigen system for tissue transplantation

The Future

What's Next for NeoStem - Opportunities

- License new stem cell technologies and pharmaceuticals
  - Stem cell – therapies, cells types, technologies
  - Pharmaceutical – generic drugs, biologics, brand or novel R&D drugs
- Bolster intellectual property portfolio
- Partner to commercialize therapies in Asia
- Collaborate on stem cell discovery
- Pursue acquisitions and partnerships
- Increase global expansion
- Strengthen scientific expertise
- Conduct proof of concept studies
- Grow API business in pharmaceuticals

Comparable Companies

Chinese Pharmaceutical Companies

($ in millions, except per share data and multiples)

		Price	Revs (M)		EV/Rev		EPS		P/E	
Company Name	Ticker	05/28/10	LTM	FY10E	LTM	FY10	LTM	FY10E	LTM	FY10E
3 SBio	SSRX	$12.41	$51	$59	3.1x	2.6x	$0.59	$0.64	21.0x	19.3x
American Oriental Bioengineering	AOB	$3.10	$304	$332	0.9x	0.8x	$0.49	$0.38	6.3x	8.1x
China Pharma Holdings	CPHI	$2.99	$64	$74	2.0x	1.7x	$0.49	$0.49	6.1x	6.1x
China Sky One Medical	CSKI	$12.66	$134	$156	1.1x	0.9x	$2.09	$2.26	6.1x	5.6x
Simcere Pharmaceutical Group	SCR	$8.44	$273	$299	1.8x	1.7x	$0.23	$0.35	36.7x	23.8x
Sinovac Biotech	SVA	$4.04	$82	$67	1.5x	1.8x	$0.45	$0.29	9.0x	14.1x
Mean					1.7x	1.6x			14.2x	12.8x
Median					1.6x	1.7x			7.7x	11.1x

Source: Thomson One, company reports.

Stem Cell Therapeutic Companies

	Cytori	StemCells, Inc	Geron
Stem Cell Source	Adult (Autologous) Mesenchymal	Adult brain tissue	Embryonic
Targeted Segments	System for Collection	Therapeutics	Therapeutics
Targeted Geographies	U.S. Europe	U.S.	U.S.
Other Pharmaceuticals	None	None	Cancer (Phase II)
LTM Revenue	$14 million	$1 million	$2 million
Appx Enterprise Value	> $300 million	$100 million	> $400 million

Sources: Capital IQ and company websites

Cord Blood Stem Cell Banking Companies

- **China Cord Blood (NYSE: CO)**
  - Acquired by Pantheon China Acquisition Corp. in June 2009
  - 9/30/09 LTM revenue = $34.3 million
  - Current enterprise value = ~$350 million (10.2x LTM revenue)

- **ViaCell, Inc.**
  - Acquired by PerkinElmer, Inc. in October 2007
  - Transaction size = ~$300 million (5.1x LTM revenue at acquisition)
  - Premium of ~36% over market cap prior to announcement

Source: Capital IQ

Investment Highlights

- **Adult stem cell platforms offer high margin, near and long-term revenue opportunities**
  - 2010 planned launches – orthopedic, anti-aging and cosmetic therapies in PRC and Taiwan
  - Future – innovative VSEL™ technology therapies for cardiovascular, stroke, wound healing
- **Leading U.S. provider of adult stem cell collection and storage services**
  - Provides ongoing revenue stream, deepens knowledge base, creates potential customer pool for future therapeutic applications
- **Majority ownership interest in profitable and growing pharma business**
  - Over $61 million in revenues for full year 2009 (unaudited)
  - 7 new products in pipeline (2 approved and pending summer 2010 launch) and several others under in-licensing negotiation
  - Benefit from $124 billion China healthcare spending initiative
- **Partnerships/collaborations in China to accelerate development & launch timelines**
  - Favorable regulatory and commercial landscape in China
- **Strong management team, advisors and board with significant U.S. and China experience**

Contact Information

NeoStem, Inc.

Robin Smith, MD, MBA
Chairman & CEO
Phone: (212) 584-4174
Email: rsmith@neostem.com
http://www.neostem.com

CCG Investor Relations, Inc.

Lei Huang
Account Manager
Phone: (646) 833-3417 (New York)
Email: lei.huang@ccgir.com
http://www.ccgir.com

Crocker Coulson
President
Phone: (646) 213-1915 (New York)
Email: crocker.coulson@ccgir.com

Thank You

NEOSTEM, INC. (“NBS”)

Investor Presentation

NeoStem
YOUR CELLS • YOUR USE • YOUR LIFE
WWW.NEOSTEM.COM